These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12840547)

  • 21. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology.
    Newman J; Rissman RA; Sarsoza F; Kim RC; Dick M; Bennett DA; Cotman CW; Rohn TT; Head E
    Acta Neuropathol; 2005 Aug; 110(2):135-44. PubMed ID: 15986225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies.
    Shao CY; Crary JF; Rao C; Sacktor TC; Mirra SS
    J Neuropathol Exp Neurol; 2006 Apr; 65(4):327-35. PubMed ID: 16691114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
    David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
    Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers.
    Ramage SN; Anthony IC; Carnie FW; Busuttil A; Robertson R; Bell JE
    Neuropathol Appl Neurobiol; 2005 Aug; 31(4):439-48. PubMed ID: 16008828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silver stains distinguish tau-positive structures in corticobasal degeneration/progressive supranuclear palsy and in Alzheimer's disease--comparison between Gallyas and Campbell-Switzer methods.
    Uchihara T; Shibuya K; Nakamura A; Yagishita S
    Acta Neuropathol; 2005 Mar; 109(3):299-305. PubMed ID: 15619127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxysterols and neurodegenerative diseases.
    Björkhem I; Cedazo-Minguez A; Leoni V; Meaney S
    Mol Aspects Med; 2009 Jun; 30(3):171-9. PubMed ID: 19248803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery.
    de la Monte SM; Jhaveri A; Maron BA; Wands JR
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):272-83. PubMed ID: 17413318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau, a biological marker of neurodegenerative diseases.
    Delacourte A
    Handb Clin Neurol; 2008; 89():161-72. PubMed ID: 18631741
    [No Abstract]   [Full Text] [Related]  

  • 30. Human brain tissue microarrays as a platform to investigate diseases of the nervous system.
    Martikainen P; Louhelainen AM; Kauppinen T; Alafuzoff I
    Brain Res; 2006 May; 1089(1):33-43. PubMed ID: 16643868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats.
    Head E; Moffat K; Das P; Sarsoza F; Poon WW; Landsberg G; Cotman CW; Murphy MP
    Neurobiol Aging; 2005 May; 26(5):749-63. PubMed ID: 15708450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.
    Forman MS; Trojanowski JQ; Lee VM
    Nat Med; 2004 Oct; 10(10):1055-63. PubMed ID: 15459709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology.
    Pittock SJ; Parrett T; Adler CH; Parisi JE; Dickson DW; Ahlskog JE
    Mov Disord; 2004 Jun; 19(6):695-9. PubMed ID: 15197711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Seppi K; Puschban Z; Stefanova N; Scherfler C; Mueller J; Poewe W; Wenning GK
    Nat Med; 2001 Feb; 7(2):132. PubMed ID: 11175818
    [No Abstract]   [Full Text] [Related]  

  • 35. Interface between tauopathies and synucleinopathies: a tale of two proteins.
    Galpern WR; Lang AE
    Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of protein aggregation in neurodegenerative diseases.
    Deng HX; Bigio EH; Siddique T
    Methods Mol Biol; 2011; 793():259-72. PubMed ID: 21913106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of polyunsaturated fatty acids for misfolding protein aggregations: implication for neurodegenerative diseases.
    Kim YJ; Takahashi R
    Ann N Y Acad Sci; 2006 Nov; 1086():11-20. PubMed ID: 17185502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
    Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
    Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-protein/A4 deposits are not associated with hyperphosphorylated tau in somatostatin neurons in the hypothalamus of Alzheimer's disease patients.
    van de Nes JA; Konermann S; Nafe R; Swaab DF
    Acta Neuropathol; 2006 Feb; 111(2):126-38. PubMed ID: 16456666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture.
    Pountney DL; Raftery MJ; Chegini F; Blumbergs PC; Gai WP
    Acta Neuropathol; 2008 Dec; 116(6):603-14. PubMed ID: 18836734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.